# Rituximab Combined With Chidamide and Lenalidomide for r/r AITL

> **NCT04319601** · NA · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 26 (estimated)

## Conditions studied

- Angioimmunoblastic T-cell Lymphoma
- Chemotherapy Effect
- Chemotherapeutic Toxicity

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT04319601
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-13
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2021-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04319601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04319601, "Rituximab Combined With Chidamide and Lenalidomide for r/r AITL". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04319601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*